<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2546">
  <stage>Registered</stage>
  <submitdate>23/10/2009</submitdate>
  <approvaldate>23/10/2009</approvaldate>
  <nctid>NCT01001754</nctid>
  <trial_identification>
    <studytitle>Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection</studytitle>
    <scientifictitle>Randomized, Controlled Phase 2a/b Study of the Efficacy and Safety of PEG-rIL-29 Administered in Combination With Ribavirin to Treatment-Naive Subjects With Chronic Hepatitis C Virus Infection</scientifictitle>
    <utrn />
    <trialacronym>EMERGE</trialacronym>
    <secondaryid>2009-011786-80</secondaryid>
    <secondaryid>526H04</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis C, Chronic</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - PEG-rIL-29
Treatment: drugs - Peginterferon alfa-2a
Treatment: drugs - Ribavirin

Experimental: PEG-rIL-29 at 120 µg - 

Experimental: PEG-rIL-29 at 180 µg - 

Active Comparator: Peginterferon alfa-2a at 180 µg - 


Treatment: drugs: PEG-rIL-29
Weekly SC injections in combination with ribavirin for up to 48 weeks

Treatment: drugs: Peginterferon alfa-2a
Weekly SC injections in combination with ribavirin for up to 48 weeks

Treatment: drugs: Ribavirin
Daily oral administration (400-600 mg BID)

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>HCV RNA</outcome>
      <timepoint>At week 12, week 24, or week 48</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence and severity of adverse events</outcome>
      <timepoint>Through week 12, week 40, or week 48</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence and severity of adverse events and laboratory abnormalities</outcome>
      <timepoint>Up to week 72</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>HCV RNA</outcome>
      <timepoint>Up to week 72</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PD biomarkers</outcome>
      <timepoint>Up to week 72</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life assessments</outcome>
      <timepoint>Up to week 72</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum drug concentration profile</outcome>
      <timepoint>Up to week 48</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  No prior therapy for chronic HCV, other than up to 2 weeks of single-agent therapy
             with a direct-acting antiviral agent, including but not limited to, a protease or
             polymerase inhibitor

          -  HCV genotype 1, 2, 3, or 4

          -  HCV RNA =100,000 IU/mL

          -  ALT and AST =5.0 × ULN

          -  Documented absence of cirrhosis

          -  Able to comprehend the investigational nature of this study and sign an informed
             consent form</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Mixed genotype HCV infection

          -  Current or prior history of decompensated liver disease

          -  Received any investigational drug, including a direct-acting antiviral agent, within
             60 days prior to receiving study drug

          -  Positive test for hepatitis B surface antigen, human immunodeficiency virus (HIV)-1,
             or HIV2 antibody at screening

          -  Active substance abuse, such as alcohol, or inhaled or injected drugs, within 6 months

        Additional inclusion and exclusion criteria are specified in the protocol.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>600</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate>1/05/2012</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
    <hospital> - Herston</hospital>
    <hospital> - Adelaide</hospital>
    <hospital> - Camperdown</hospital>
    <hospital> - Clayton</hospital>
    <hospital> - Fitzroy</hospital>
    <hospital> - Fremantle</hospital>
    <hospital> - Greenslopes</hospital>
    <hospital> - Kogarah</hospital>
    <hospital> - Melbourne</hospital>
    <hospital> - Penrith</hospital>
    <hospital> - Perth</hospital>
    <hospital> - Westmead</hospital>
    <postcode> - Herston</postcode>
    <postcode> - Adelaide</postcode>
    <postcode> - Camperdown</postcode>
    <postcode> - Clayton</postcode>
    <postcode> - Fitzroy</postcode>
    <postcode> - Fremantle</postcode>
    <postcode> - Greenslopes</postcode>
    <postcode> - Kogarah</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - Penrith</postcode>
    <postcode> - Perth</postcode>
    <postcode> - Westmead</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Graz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Innsbruck</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Linz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wien</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pessac</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bochum</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dusseldorf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt/Main</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Goettingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hannover</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Heidelberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Koln</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mainz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Munchen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Tubingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bialystok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lancut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Raciborz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>Santurce</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucharest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Iasi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Timisoara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Majadahonda</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>ZymoGenetics</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Bristol-Myers Squibb</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Interleukin 29 (IL-29) is a substance that is produced in the body to help fight viral
      infections. The purpose of this study is to evaluate the safety and antiviral effects of
      several different doses of PEG-rIL-29 (a man-made form of IL-29) when it is given in
      combination with daily oral doses of ribavirin (an antiviral drug) to subjects with hepatitis
      C infection who have received no prior treatment for this disease.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01001754</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jan Hillson, MD</name>
      <address>ZymoGenetics</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>